Allarity Therapeutics Inc (ALLR) - Total Liabilities

Latest as of December 2025: $8.43 Million USD

Based on the latest financial reports, Allarity Therapeutics Inc (ALLR) has total liabilities worth $8.43 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ALLR year-over-year net asset growth to track the company's year-over-year net asset growth rate.

Allarity Therapeutics Inc - Total Liabilities Trend (2013–2025)

This chart illustrates how Allarity Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See ALLR cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Allarity Therapeutics Inc Competitors by Total Liabilities

The table below lists competitors of Allarity Therapeutics Inc ranked by their total liabilities.

Company Country Total Liabilities
Communication Cable Systems Indonesia Tbk PT
JK:CCSI
Indonesia Rp195.71 Billion
Telefast Indonesia 
JK:TFAS
Indonesia Rp42.65 Billion
ZECON Bhd
KLSE:7028
Malaysia RM1.24 Billion
Gale Pacific Ltd
AU:GAP
Australia AU$85.52 Million
ERSU Meyve ve Gida Sanayi AS
IS:ERSU
Turkey TL95.95 Million
O.C.C. Public Company Limited
BK:OCC
Thailand ฿178.47 Million
Hateks Hatay Tekstil Isletmeleri AS
IS:HATEK
Turkey TL1.94 Billion
Coats Group PLC
LSE:COA
UK GBX1.24 Billion

Liability Composition Analysis (2013–2025)

This chart breaks down Allarity Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Allarity Therapeutics Inc worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.13 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.86 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.46 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Allarity Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Allarity Therapeutics Inc (2013–2025)

The table below shows the annual total liabilities of Allarity Therapeutics Inc from 2013 to 2025.

Year Total Liabilities Change
2025-12-31 $8.43 Million -22.23%
2024-12-31 $10.84 Million -25.83%
2023-12-31 $14.61 Million +15.48%
2022-12-31 $12.65 Million -58.98%
2021-12-31 $30.85 Million +370.83%
2020-12-31 $6.55 Million -38.79%
2019-12-31 $10.70 Million +0.17%
2018-12-31 $10.69 Million +529.09%
2017-12-31 $1.70 Million +27.11%
2016-12-31 $1.34 Million +157.91%
2015-12-31 $518.15K +3489.03%
2014-12-31 $14.44K +15.01%
2013-12-31 $12.55K --

About Allarity Therapeutics Inc

NASDAQ:ALLR USA Biotechnology
Market Cap
$18.71 Million
Market Cap Rank
#25278 Global
#5278 in USA
Share Price
$1.21
Change (1 day)
-1.63%
52-Week Range
$0.81 - $1.97
All Time High
$1000000.00
About

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead d… Read more